杜氏肌营养不良症5年心肺功能进展与糖皮质激素作用:单中心回顾性纵向研究
该单中心回顾性纵向研究纳入2000年5月至2017年6月在伦敦大奥蒙德街医院杜博维茨神经肌肉中心随访的270例杜氏肌营养不良症男孩,排除参加任何干预性临床试验者。每日泼尼松/地夫可特组66例、间歇方案(用10天停10天)>60%治疗组182例、未用糖皮质激素组22例。结果显示每日与间歇组预测FVC%年下降率相似(分别为5.9%和6.9%/年,P=0.27),两治疗组达到预测FVC%<50%及需要无创通气的年龄均比未治疗组晚2年以上;治疗组LVFS%年下降0.53%,显著慢于未治疗组的1.17%/年(P<0.01),心肌病发生年龄治疗组16.6岁、未治疗组13.9岁(P<0.05)。
要点
- 在270例杜氏肌营养不良症男孩中,糖皮质激素治疗组(每日或间歇)达到预测FVC%<50%和需要无创通气的年龄均比未治疗组晚2年以上。
- 糖皮质激素治疗组左心室缩短分数每年下降0.53%,显著慢于未治疗组的1.17%/年(P<0.01)。
- 糖皮质激素治疗组心肌病(LVFS%<28%)发生年龄为16.6岁,未治疗组为13.9岁(P<0.05),与方案无关。
- 每日方案组与间歇方案组预测FVC%年下降率分别为5.9%和6.9%/年,差异无统计学意义(P=0.27)。
适用人群与场景
- 2000年5月至2017年6月在伦敦大奥蒙德街医院杜博维茨神经肌肉中心随访的杜氏肌营养不良症男孩。
- 排除参加任何干预性临床试验的患者。
- 糖皮质激素未治疗组定义为从未接受糖皮质激素。
- 糖皮质激素治疗组为接受地夫可特或泼尼松、每日或间歇(用10天停10天)方案治疗超过1个月者。
诊断标准与关键阈值
- 心肌病定义为左心室缩短分数(LVFS%)<28%。
- 呼吸终点为预测FVC%<50%和需要无创通气(NIV)。
处置流程与药物剂量
- 糖皮质激素治疗药物为地夫可特或泼尼松,方案为每日或间歇(用10天停10天),治疗时间超过1个月。
研究设计与关键结果
- 研究为单中心回顾性纵向研究,纳入270例杜氏肌营养不良症男孩,基线平均年龄6.2±2.3岁,中位随访时间5.6±3.5年,基线时263例可行走。
- 分组:每日糖皮质激素组66例,间歇糖皮质激素治疗>60%组182例,未治疗组22例。
- 从9岁起,每日组和间歇组预测FVC%年下降率分别为5.9%和6.9%/年,差异无统计学意义(P=0.27)。
- 每日组从更高的预测FVC%水平开始下降(与间歇组比较P<0.05),但两组达到预测FVC%<50%和需要无创通气的年龄相似,均比未治疗组晚2年以上。
- 糖皮质激素治疗组LVFS%每年下降0.53%,与方案无关,显著慢于未治疗组的1.17%/年(P<0.01)。
- 心肌病发生年龄在糖皮质激素治疗组为16.6岁(P<0.05,与方案无关),未治疗组为13.9岁。
证据类型、等级与局限
- 证据类型:单中心回顾性纵向研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,糖皮质激素无论采用何种方案,均显著改善杜氏肌营养不良症男孩的呼吸功能,并延迟无创通气需求和心肌病的发生。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Corticosteroids (CSs) have prolonged survival and respiratory function in boys with Duchenne muscular dystrophy (DMD) when compared with CSs-naïve boys.
RESEARCH QUESTION: The differential impact of frequently used CSs and their regimens on long-term (> 5 years) cardiorespiratory progression in children with DMD is unknown.
STUDY DESIGN AND METHODS: This was a retrospective longitudinal study including children with DMD followed at Dubowitz Neuromuscular Centre, Great Ormond Street Hospital London, England, from May 2000 to June 2017. Patients enrolled in any interventional clinical trials were excluded. We collected patients' anthropometrics and respiratory (FVC, FVC % predicted and absolute FVC, and noninvasive ventilation requirement [NIV]) and cardiac (left ventricular shortening function [LVFS%]) function. CSs-naïve patients had never received CSs. Patients who were treated with CSs took either deflazacort or prednisolone, daily or intermittently (10 days on/10 days off) for > 1 month. Average longitudinal models were fitted for yearly respiratory (FVC % predicted) and cardiac (LVFS%) progression. A time-to-event analysis to FVC % predicted < 50%, NIV start, and cardiomyopathy (LVFS% < 28%) was performed in CS-treated (daily and intermittent) vs CS-naïve patients.
RESULTS: There were 270 patients, with a mean age at baseline of 6.2 ± 2.3 years. The median follow-up time was 5.6 ± 3.5 years. At baseline, 263 patients were ambulant. Sixty-six patients were treated with CSs daily, 182 patients underwent CSs intermittent > 60% treatment, and 22 were CS-naïve patients. Yearly FVC % predicted declined similarly from 9 years (5.9% and 6.9% per year, respectively; P = .27) in the CSs-daily and CSs-intermittent groups. The CSs-daily group declined from a higher FVC % predicted than the CSs-intermittent group (P < .05), and both reached FVC % predicted < 50% and NIV requirement at a similar age, > 2 years later than the CS-naïve group. LVFS% declined by 0.53% per year in the CSs-treated group irrespective of the CSs regimen, significantly slower (P < .01) than the CSs-naïve group progressing by 1.17% per year. The age at cardiomyopathy was 16.6 years in the CSs-treated group (P < .05) irrespective of regimen and 13.9 years in the CSs-naïve group.
INTERPRETATION: CSs irrespective of the regimen significantly improved respiratory function and delayed NIV requirement and cardiomyopathy.
参考来源
- Trucco F, Domingos JP, Tay CG, et al. Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study. Chest. 2020. PMID: 32387519. doi:10.1016/j.chest.2020.04.043
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。